Latest technology reporting
Evidence-led coverage of biotechnology, AI infrastructure, energy, robotics, devices and brain–computer interfaces.
-
NVIDIA’s DSX POD Moves AI Factories Onto the Assembly Line
NVIDIA says partners can factory-integrate Vera Rubin computing, networking, power and liquid cooling into modular containers. The claimed 14-day site deployment starts only after utilities and foundations are ready.
-
Human Argonaute Becomes a Programmable RNA Editor in Cells
The ALTER system repurposes human Argonaute 2 to guide C-to-U edits in messenger RNA. It outperformed two Cas13 editors in one cultured-cell comparison, but remains early laboratory research.
-
Recordanelles Give Human Cells a Transcriptome Memory
A synthetic organelle preserved a broad sample of messenger RNA for days inside cultured human cells, allowing later sequencing to recover transient gene activity. It is a research tool, not a therapy.
-
Rina-S’s Phase III Win Raises the Bar for Platinum-Resistant Ovarian Cancer
Rina-S cut the relative risks of progression and death versus chemotherapy in a 584-person Phase III trial. The result is important, but it remains a topline company disclosure rather than a regulatory approval.
-
HPE’s Mixed-GPU Private Cloud Makes Scheduling the Scarce Resource
HPE Private Cloud AI can now combine H200 and RTX PRO 6000 Blackwell GPUs in one cluster, using KAI Scheduler to assign work by quotas and priorities. The update shifts attention from buying accelerators to governing who gets them.
-
Google’s A5X Plan Turns AI Scale Into a Networking Claim
Google Cloud says A5X instances built on NVIDIA Vera Rubin will become generally available in November, with Virgo networking designed for up to 80,000 GPUs at one site and 960,000 across sites. Those are architecture limits, not deployed capacity.
-
IRENA’s 2026 Outlook Says the Grid, Not Solar Panels, Is the Transition Bottleneck
IRENA’s 2026 pathway puts electrification, efficiency, grids, storage and flexibility on the same critical path. Renewable capacity rises sharply in the scenario, but the report is a roadmap—not a forecast or a guarantee.
-
Fervo’s First Cape Station Block Turns Enhanced Geothermal Into Operating Power
Fervo’s first 33 MW GeoBlock at Cape Station has reached contractual commercial operation. It is a real operating milestone for enhanced geothermal, while the remaining 467 MW and long-term economics are still to be proven.
-
Human-Embryo Base Editing Improves Precision but Still Triggers Safety Alarms
A Nature study achieved efficient adenine base editing in research-stage human embryos without the large deletions typical of DNA-cutting CRISPR. Rare chromosome damage, mosaic off-target edits and embryo arrest still rule out reproductive use.
-
Tarlatamab Combination Extends Survival in First-Line Small-Cell Lung Cancer
In the Phase III DeLLphi-305 trial, tarlatamab plus durvalumab extended median overall survival to 21.1 months after initial chemotherapy. The benefit was substantial, alongside higher serious treatment-related toxicity and frequent cytokine release syndrome.
-
Personalised mRNA Cancer Vaccine Cuts Melanoma Recurrence Risk in Phase III
A 1,137-person Phase III trial found that adding an individualised mRNA therapy to Keytruda reduced the risk of melanoma recurrence or death by 42%. The result is important, but it is not yet an approval or proof of benefit in other cancers.
-
Intel’s 480 GB Inference GPU Makes Memory Capacity the Main Bet
Intel’s GPU D-series targets large-model inference with unusually high memory capacity and air-cooled PCIe deployment, but independent benchmarks are still missing.